Aurobindo Pharma's Subsidiary, CuraTeQ Biologics, Signs Marketing and Distribution Agreement with STADA for Biosimilars in EU Territories

CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd, has entered into a marketing and distribution agreement with STADA Arzneimittel AG, a leading European healthcare and pharmaceuticals company. The agreement covers two EMA approved biosimilars developed by CuraTeQ and will see STADA market and distribute these in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar. This agreement is expected to expand CuraTeQ’s market reach, drive revenue growth, and leverage STADA’s established distribution network in EU markets.